You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《國家政策》國家醫保局稱繼續降低治療藥品價格
國家醫療保障局表示,將繼續降低疫苗、核酸檢測等價格。多隻醫藥股下跌,復星醫藥(02196.HK)跌逾6%,報32.4元,藥明康德(02359.HK)跌近5%,報112.2元,國藥控股(01099.HK)跌逾1%,報17.4元。 國家醫保局黨組在《求是》2022年第8期刊發署名文章稱,將繼續降低疫苗、核酸檢測、抗原檢測、治療藥品價格,減輕防疫負擔,繼續落實「兩個確保」,及時將治療新藥臨時納入支付範圍,幫助實現疫情防控「四早」,接續做好疫苗和接種費用保障工作,配合相關部門精準提高易感人羣接種水平,持續拓寬線上服務渠道,做好醫保服務場所疫情防控,確保疫情期間待遇不打折、支付不中斷、服務不聚集。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account